Sanofi
$534M 13F equity value
11 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Sanofi covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| MGTX | MeiraGTx Holdings plc | 12,197,737 | $165M | 30.9% |
| INBX | Inhibrx Biosciences, Inc. | 1,157,926 | $110M | 20.5% |
| NVAX | Novavax | 6,880,481 | $65M | 12.1% |
| ANAB | AnaptysBio | 821,917 | $55M | 10.4% |
| ODTX | Odyssey Therapeutics Inc. | 1,991,918 | $37M | 7.0% |
| AGMB | Agomab Therapeutics NV | 2,783,096 | $36M | 6.8% |
| MPLT | MapLight Therapeutics Inc. | 912,041 | $33M | 6.1% |
| TRAX | First Tracks Biotherapeutics Inc. | 821,917 | $17M | 3.1% |
| IMRX | Immuneering Corp | 2,708,559 | $14M | 2.5% |
| QTTB | Q32 Bio Inc. | 244,083 | $3M | 0.6% |
Track Sanofi's 13F portfolio: $534M in reported holdings, 11 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}